Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
26-28 August, 2025
APGA Annual ConferenceAPGA Annual Conference
Not Confirmed
Not Confirmed
20-23 July, 2025
Not Confirmed
Not Confirmed
24-25 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
26-28 August, 2025
APGA Annual ConferenceAPGA Annual Conference
Industry Trade Show
Not Confirmed
20-23 July, 2025
Industry Trade Show
Not Confirmed
24-25 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
14 Jul 2025
// ECONOMICTIMES
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharma-settles-litigation-with-incyte-corp/articleshow/122440188.cms
10 Jul 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250710532230/en/Incyte-to-Report-Second-Quarter-Financial-Results
26 Jun 2025
// CONTRACTPHARMA
https://www.contractpharma.com/breaking-news/incyte-appoints-bill-meury-chief-executive-officer/
26 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250626449520/en/Incyte-Appoints-Bill-Meury-Chief-Executive-Officer-Herv-Hoppenot-to-Retire
20 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250620553806/en/Update-on-FDA-Review-of-Ruxolitinib-Cream-Opzelura-for-Children-Ages-2-11-with-Atopic-Dermatitis
19 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250615896694/en/Incyte-Announces-FDA-Approval-of-Monjuvi-tafasitamab-cxix-in-Combination-with-Rituximab-and-Lenalidomide-for-Patients-with-Relapsed-or-Refractory-Follicular-Lymphoma
Inspections and registrations
ABOUT THIS PAGE